Want to see ELTP full AI Analyst Report?
Total Valuation
Elite Pharmaceuticals has a market cap or net worth of $331.76M. The enterprise value is $378.71.
Market Cap$331.76M
Enterprise Value$378.71
Share Statistics
Elite Pharmaceuticals has 1,077,136,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,077,136,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Elite Pharmaceuticals’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is 32.33%.
Return on Equity (ROE)0.45
Return on Assets (ROA)0.32
Return on Invested Capital (ROIC)32.33%
Return on Capital Employed (ROCE)0.41
Revenue Per Employee2.29M
Profits Per Employee690.35M
Employee Count65
Asset Turnover1.08
Inventory Turnover<0.01
Valuation Ratios
The current PE Ratio of Elite Pharmaceuticals is 5.7. Elite Pharmaceuticals’s PEG ratio is -0.00757.
PE Ratio5.7
PS Ratio2.61
PB Ratio3.93
Price to Fair Value3.93
Price to FCF0.02
Price to Operating Cash Flow17.31
PEG Ratio-0.00757
Income Statement
In the last 12 months, Elite Pharmaceuticals had revenue of 148.87M and earned 44.87M in profits. Earnings per share was 0.04.
Revenue148.87M
Gross Profit73.48M
Operating Income49.96M
Pretax Income56.81M
Net Income44.87M
EBITDA51.98M
Earnings Per Share (EPS)0.04
Cash Flow
In the last 12 months, operating cash flow was 19.04M and capital expenditures -1.52M, giving a free cash flow of 17.53M billion.
Operating Cash Flow19.04M
Free Cash Flow17.53M
Free Cash Flow per Share0.02
Dividends & Yields
Elite Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-46.84%
50-Day Moving Average0.37
200-Day Moving Average0.42
Relative Strength Index (RSI)23.30
Average Volume (3m)951.20K
Important Dates
Elite Pharmaceuticals upcoming earnings date is Nov 17, 2026, TBA (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 17, 2026
Ex-Dividend Date―
Financial Position
Elite Pharmaceuticals as a current ratio of 6.45, with Debt / Equity ratio of 2.53%
Current Ratio6.45
Quick Ratio-1.22K
Debt to Market Cap<0.01
Net Debt to EBITDA-573.16
Interest Coverage Ratio125.95
Taxes
In the past 12 months, Elite Pharmaceuticals has paid 11.94M in taxes.
Income Tax11.94M
Effective Tax Rate0.21
Enterprise Valuation
Elite Pharmaceuticals EV to EBITDA ratio is -565.68, with an EV/FCF ratio of -1.29.
EV to Sales-197.51
EV to EBITDA-565.68
EV to Free Cash Flow-1.29
EV to Operating Cash Flow-1.24
Balance Sheet
Elite Pharmaceuticals has $38.94M in cash and marketable securities with $2.65M in debt, giving a net cash position of $36.29M billion.
Cash & Marketable Securities$38.94M
Total Debt$2.65M
Net Cash$36.29M
Net Cash Per Share$0.03
Tangible Book Value Per Share-$4.37
Margins
Gross margin is 43.21%, with operating margin of 33.56%, and net profit margin of 30.14%.
Gross Margin43.21%
Operating Margin33.56%
Pretax Margin38.16%
Net Profit Margin30.14%
EBITDA Margin34.92%
EBIT Margin33.56%
Analyst Forecast
The average price target for Elite Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast33.72%
EPS Growth Forecast―